

Special Issue

Evaluation of Vaccine Efficacy, Safety and Immunogenicity against Influenza and COVID-19

Message from the Guest Editor

Prophylactic vaccines against influenza and COVID-19 have been given to billions of individuals and are effective for the prevention of severe disease. While the safety and efficacy of current influenza vaccines are established based on decades of use, new vaccine concepts to achieve higher efficacy and preferentially more universal protection have a yet to be defined immunogenicity, safety and efficacy profile. Some of these new vaccine concepts have been used for the rapidly developed and licensed COVID-19 vaccines. These have shown to be safe with a high efficacy against severe disease; however, safety concerns of rare cases of myocarditis and vaccine-induced immune thrombotic thrombocytopenia (VITT) shortly after vaccination became apparent, requiring further research to understand their etiology. SARS-CoV-2 vaccines have shown in part waning immunity and reduced efficacy against variants of concern, requiring the development of strategies to improve and further develop these new vaccine concepts and explore new ones.

Guest Editor

Dr. Roland Zahn
Janssen Prevention Center, 2333 CN Leiden, The Netherlands

Deadline for manuscript submissions

closed (31 October 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/131911

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).